Results 251 to 260 of about 27,710,413 (387)

한국에서의 Human T - Cell Leukemia Virus Type - 1 ( HTLV - 1 ) 에 대한 혈청학적 및 역학에 관한 연구 [PDF]

, 1986
이영열, 이홍복, 서철원, 규경채, 김은실, 박선양, 김병국, 최강원, 김노경, 이문호, 조한익, 이성열, 고월청, 야마구찌이찌세이   +13 more
openalex  

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Reduced EZH2 Expression in Circulating CD8-Positive T Cells and Monocytes in Psoriasis. [PDF]

Exp Dermatol
Yamamoto T, Toyoshima R, Li L, Koyama A, Sato S, Shibata S.   +5 more
europepmc   +1 more source

Efficiently ReversingImmunotherapy Resistance inLung Cancer by an Inhalable 2D Molybdenum Disulfide T Cell HyperactivationPlatform

Yanze Yin (12627331), Changjie Yang (14172897), Zhimin Chen (682487), Han Du (187162), Gening Jiang (431928), Alberto Bianco (151604), Jie Dai (54224), Ding-Kun Ji (1780642)   +7 more
openalex   +1 more source

Real-world safety and mortality outcomes of CAR-T cell therapies versus bispecific antibodies in DLBCL: Insights from the faers database [PDF]

Fatma Temiz, Işık Atagündüz, Tayfur Toptaş   +2 more
openalex   +1 more source

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

Nature, 2016
S. Im, M. Hashimoto, Michael Y. Gerner, Michael Y. Gerner, JungHwa Lee, H. Kissick, Matheus C. Bürger, Q. Shan, J. Hale, Judong Lee, T. Nasti, A. Sharpe, A. Sharpe, G. Freeman, R. Germain, H. Nakaya, Hai-hui Xue, R. Ahmed   +17 more
semanticscholar   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

The development of CAR T cells for patients with CNS malignancies. [PDF]

Nat Rev Clin Oncol
Binder ZA, Bagley SJ, Foster JB, O'Rourke DM.   +3 more
europepmc   +1 more source

Peripheral blood innate and adaptive T cell responses to zoster vaccines.

Michael J. Johnson (5818168), Megan Crotteau (22794619), Debashis Ghosh (32244), Thao Vu (3363083), Luke Trinity (6792770), Radu Marches (11368465), Duygu Ucar (3164778), Myron J. Levin (17674347), Adriana Weinberg (328665)   +8 more
openalex   +1 more source

Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas

New England Journal of Medicine, 2017
S. Schuster, J. Svoboda, E. Chong, S. Nasta, A. Mato, Ö. Anak, J. Brogdon, Iulian Pruteanu-Malinici, V. Bhoj, D. Landsburg, M. Wasik, B. Levine, S. Lacey, J. Melenhorst, D. Porter, C. June   +15 more
semanticscholar   +1 more source